| Date Filed | Type | Description |
| 02/12/2010 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2010 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/28/2009 |
25-NSE
| Form 25-NSE -- |
| 07/13/2009 |
8-K
| Quarterly results |
| 06/22/2009 |
8-K
| Other Events |
| 06/16/2009 |
8-K
| Cost Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits |
| 06/15/2009 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
| 05/29/2009 |
SC 13G
| BB BIOVENTURES L P reports a |
| 05/22/2009 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...|
Docs:
|
"Oscient Pharmaceuticals Receives NASDAQ Letter Regarding Delay in Filing Form 10-Q Waltham, Mass., May 22, 2009 - Oscient Pharmaceuticals Corporation has received notification from the Listings Qualifications Department of The NASDAQ Stock Market LLC that since the Company has not filed its Form 10-Q for the period ended March 31, 2009, the Company is no longer in compliance with Marketplace Rule 5250. The Company has 60 calendar days, or until July 20, 2009, to submit a plan to regain compliance. Following such submission, NASDAQ may provide the Company with up to 180 calendar days from the filing's due date, or until November 11, 2009, to regain compliance. If NASDAQ does not accept the Company's plan to regain compliance, the Company will receive written notification of delisting from N..." |
|
| 05/19/2009 |
SC 13G/A
| DellaCamera Capital Management, LLC reports a 3.6% stake in Oscient Pharmaceuticals Corporation. |
| 05/18/2009 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 2.2% stake in Oscient Pharmaceuticals |
| 05/15/2009 |
8-K
| Form 8-K -- Current report |
| 05/01/2009 |
8-K
| Form 8-K -- Current report |
| 04/29/2009 |
10-K/A
| Annual Report for the period ended December 31, 2008 [amend] |
| 03/27/2009 |
8-K
| Form 8-K -- Current report |
| 03/25/2009 |
10-K
| Annual Report for the period ended December 31, 2008 |
| 03/25/2009 |
8-K
| Quarterly results |
| 03/23/2009 |
8-K
| Form 8-K -- Current report |
| 02/13/2009 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 02/13/2009 |
8-K
| Form 8-K -- Current report |
| 02/13/2009 |
SC 13G/A
| Form SC 13G/A -- Statement of acquisition of beneficial ownership by individuals [amend] |
| 02/05/2009 |
SC 13G
| ZAZOVE ASSOCIATES LLC reports a 15.9% stake in Oscient Pharmacuetical Corporation |
| 02/03/2009 |
8-K
| Form 8-K -- Current report |
| 02/03/2009 |
SC 13G/A
| RG CAPITAL MANAGEMENT LP reports a 6% stake in Oscient Pharmaceuticals Corporation |
| 01/29/2009 |
SC 13G/A
| CITIGROUP INC reports a 6.1% stake in Oscient Pharmaceuticals Corporation |
| 01/15/2009 |
SC 13G
| GLG Partners LP reports a 10.6% stake in Oscient Pharmaceuticals Corporation |
| 01/15/2009 |
8-K
| Other Events, Financial Statements and Exhibits |
| 12/23/2008 |
8-K
| Form 8-K -- Current report |
| 12/23/2008 |
SC 13G/A
| AKANTHOS CAPITAL MANAGEMENT LLC reports a 9.9% stake in OSCIENT PHARMACEUTICALS CORP |
| 12/16/2008 |
8-K
| Form 8-K -- Current report |
| 12/15/2008 |
SC 13G
| AKANTHOS CAPITAL MANAGEMENT LLC reports a 19.7% stake in OSCIENT PHARMACEUTICALS CORP |
| 12/11/2008 |
SC 13G/A
| OSCIENT PHARMACEUTICALS CORP reports a 10% stake in Oscient Pharmaceuticals |
| 12/10/2008 |
SC 13G
| OSCIENT PHARMACEUTICALS CORP reports a 15.2% stake in Oscient Pharmaceuticals Corporation |
| 12/08/2008 |
SC 13G/A
| OSCIENT PHARMACEUTICALS CORP reports a 6.8% stake in Oscient Pharmaceuticals Corporation |
|